Q1 2022 Viridian Therapeutics Inc Earnings Call
Okay.
Welcome to the Peridium Therapeutics first quarter 2022 conference call.
All participants will be in listen only mode.
Should you need assistance please.
Specialist by pressing the star key powered by Veeva.
After todays presentation, there will be an opportunity to ask questions.
You ask a question you May press Star then one on your telephone keypad.
Drawing your question. Please press Star then two please note our feedback is being recorded it is now my pleasure to introduce your host John Jordan, Vice President of Investor Relations and corporate communications.
Please go ahead Sir.
Thank you Debbie good afternoon, everyone and welcome to our first quarter 2022 conference calls today. After the market closed we issued a press release, providing our first quarter of 2022 financial results and business update a replay of today's call will be available on our Investor Relations section of our website approximately one.
Our after its completion.
After our prepared remarks, we will open up the call for Q&A.
Before we begin I'd like to remind everyone that this conference call and webcast will contain forward looking statements about the company.
These statements are subject to risks and uncertainties that could cause actual results to differ.
Please note that these statements reflect our opinions only as of today.
Except as required by law, we disclaim any obligation to update or revise these statements in light of new information or future events.
Factors that could cause actual results or outcomes to differ materially from those expressed in or implied by such forward looking statements are discussed in greater detail in our most recent filings on Form 10-K, and our other reports filed with the SEC.
I would now like to turn the call over to Jonathan violin, President and Chief Executive Officer of burden.
Thanks, Tom and good afternoon, everyone. Thanks for joining us on our first quarter 2022 conference call. I'm also joined today by Christian humor, our Chief Financial Officer, and Chief Business Officer.
We will begin with a brief update on the business, including recent and upcoming milestones and the progress we're making in advancing our lead candidates for thyroid eye disease or Ted then.
And then Christian will review, our first quarter financial results then we'll open the call for questions.
First and foremost I'm excited for the data we expect to deliver in the coming months, we have multiple data readouts that we expect will confirm the potential of our antibodies to significantly advance the treatment of thyroid eye disease.
After a very productive 2021, we continued our momentum in the first quarter with substantial progress in our phase <unk> proof of concept clinical trial for <unk>, one and the initiation of our first in human clinical trial for <unk>.
Both trials are poised to deliver topline data in the third quarter.
We believe these two trials will provide the initial evidence to establish the <unk> and <unk> as meaningful therapeutic advancements in treating thyroid eye disease.
I'd like to spend a few minutes reviewing each of our <unk> program and the significance of the ongoing trials for each asset starting with Vod and over one.
Data from previous oncology trials, and our preclinical studies indicate that the other one is the same mechanism of action and similar pharmacokinetics in humans is deposit the only therapy approved by the FDA for test.
The key difference for <unk> is higher affinity with our own data and previously published data showed that the <unk> has suddenly animal or affinity and potency against the IGF. One are the targeted mechanism of action.
This higher potency may reduce the dose required to deliver efficacy and Ted patients, we see an opportunity to develop a one is a differentiated intravenous products addressing the need we've heard from stakeholders for a less burdensome and potentially safer dosing regimen.
In December we announced the dosing of the first subject in a phase <unk> proof of concept clinical trial for <unk>.
This trial is designed to evaluate the safety Tolerability pharmacokinetics, pharmacodynamics and efficacy of one.
It includes both healthy volunteers and randomized placebo controlled cohorts of 10 patients and is assessing multiple measures of the signs and symptoms of tests, including proptosis or bulging device characteristic of Ted.
Over the past several months, we completed dose escalation in enrollment in healthy volunteers and continue to enroll 10 patients.
We expect to deliver top line proof of concept data from two cohorts of 10 patients in the third quarter.
Now have 11 sites active in recruiting similar to the number of sites and the deposit phase III trial, and we're working with some of the top enrolling sites in that trial.
Some of the site activation took longer than we initially expected we continue to see strong engagement from investigators and interest from patients importantly, we've been very pleased that once open the rate of screening and enrolling patients per site has met our expectations. So we're very confident in our enrollment projections and in sharing top line data in the third quarter.
Well, we eagerly anticipate reviewing our first data from Ted patients I am pleased to share today, some highly encouraging interim data for the healthy volunteer portion of this trial, which includes 13 subjects, receiving two doses of placebo or Vod and over one 310 or 20 Meg per kg where.
We're very encouraged by the safety and Tolerability <unk> seen to date there've been no drug related adverse events associated with hyperglycemia hearing loss or muscle spasms at any dose, including the top dose of 20 milligrams per kilogram.
Other adverse events have been generally comparable to placebo and to date, there have been no infusion reactions or serious adverse events.
In addition to this promising safety profile, we see robust increases in IGF, one plasma levels, a biomarker for IGF Oner inhibition.
Interim data show a rapid seven fold increase in IGF, one from baseline at all doses tested including three mix per kg, suggesting doses as low as three Meg per kg are sufficient to achieve maximal IGF oner inhibition.
Moreover, maximal in addition was achieved rapidly and was sustained throughout the two dose treatment period.
Increases in IGF, one were observed in patients treated with placebo.
The robust IGF one response at three months per kit is consistent with data for this antibody in oncology patients and suggested this does can be highly effective and Ted patients. This is important because it could allow us to advance <unk> one as a self administered subcutaneous injection. In addition to intravenous administration.
We've included the preliminary safety and IGF, one data and our updated corporate presentation, which is available on our website.
This interim healthy volunteer data increases our excitement for our upcoming proof of concept results that confirm our expectations for the safety in potency of our molecule.
And based on these results we now plan to evaluate an additional cohort of 10 patients at a dose of three Meg per kg. Following the completion of the proof of concept portion of the ongoing trial.
So we expect to deliver proof of concept data from two cohorts in the third quarter and data from the low dose three make particular heart in the fourth quarter.
As a reminder, the proof of concept portion of this trial includes two cohorts age.
Ted patients each randomized in a three to one ratio to receive one or placebo.
The first cohort will include two infusions of 10 Meg per kg a little one in the second cohort will include two infusions of 'twenty makes per Kid of a one.
We're assessing multiple efficacy endpoints and we'll report data at six weeks after two infusions of one well.
We will report the same endpoint do you use to evaluate to Tessa focusing on mean change from baseline in Proptosis reduction, but will also report proptosis responder rate clinical activity score and diplopia.
Our goal is to see efficacy signals comparables to cause it six weeks in particular, we're focused on change from baseline and practices for which the three to cause the datasets phase to phase III and phase III Open label extension showed very consistent changes at six weeks with a mean of one seven to $1 nine millimeters. So that's the range.
We're aiming for.
It would confirm that we can recapitulate the rapid improvement in Ted sometimes that's a pet that has demonstrated and position us to quickly advance our program towards pivotal trials with the goal of being second to market.
Since dependent as the only entrants and a rapidly growing market already annualizing at $2 billion in the U S. Just two years into launch.
We believe that showing the Rd, one proof of concept data similar to tether would be major value, creating events for us. We know we have a compelling product with the potential to be the second entrant in a large rapidly growing market.
And we also know we have multiple opportunity to differentiate our product profile to enhance our market position.
To this end, we're already preparing our one for pivotal trials, including manufacturing material at commercial scale, assuming positive proof of concept data and we anticipate advancing our program rapidly.
We intend to bring to market with a differentiated product profile and plan to assess multiple dosing regimens in parallel.
Fewer infusions or different routes of administration will be a welcome advancement protect patients.
We look forward to discussing our phase III plant following a proof of concept trial readout.
Let's now turn to the Rd N O two our next generation IGF one of our targeted program.
Oh, two is a humanized monoclonal antibody that incorporates validate is half life extension technology and is designed to support administration as a convenient low volume subcutaneous injection for the treatment of Ted.
Based on the Dr. Tien Oh, one healthy volunteer data, we shared a few moments ago. We're now increasingly optimistic that a low dose of a well one might allow a self administered subcutaneous dosing paradigm and we're excited that it has the potential to move rapidly and become the first subcutaneous therapy for thyroid eye disease.
They are D N O two.
With its half life extension technology may represent the next generation best in class product is it has the potential for less frequent subcutaneous dosing than any cell therapy, including VR Dan over one.
We expect to show the pharmacokinetic benefits of this molecule in our ongoing phase one first in human trial.
We announced the dosing of the first subject in this trial in March.
The trial is a single ascending dose study to explore safety tolerability pharmacokinetics and pharmacodynamics of intravenously administered <unk> in healthy volunteers.
We've completed dose escalation and expect to announce topline data from this trial in the third quarter either concurrently with our following shortly after I retire at the end of one proof of concept readout.
We expect that the results of this trial will demonstrate how well half life extension technology improves pharmacokinetics compared to a traditional IGF oner antibody.
And these data will inform the dose and dosing frequency of a low volume subcutaneous product.
We're on track to have a sub Q drug product ready in early fourth quarter, and we expect to be ready to initiate a subcutaneous proof of concept trial and Ted patients shortly thereafter.
Okay.
Oh, one I know of two programs. We believe we have a compelling 10 portfolio with intravenous and subcutaneous options that can compete across all settings of care.
I'm grateful for the excellent work the Meridian team has done to advance our programs and also for the investigators volunteers and patients who are participating in our trials.
Moving to our programs beyond Ted we're expanding our pipeline by discovering and developing more convenient next generation antibodies for indications in which proof of concept for the targeted mechanism of action already exists.
For both our Vod and <unk>, four and <unk> five programs, we see opportunities to advance patient care and of all treatment paradigms with a new best in class entrants and we continue to progress. These programs in discovery stage, we will provide updates as these programs mature for now we remain laser focused on delivering on our Ted portfolio opportunity.
Yeah.
I'll now turn the call over to Christian who will discuss our financial results for the first quarter Christian.
Thank you Jonathan good afternoon, everyone I want to open up our comments by stating that we ended the first quarter with $175 million in cash cash equivalents and short term investments as of March 31st 2022.
This puts us in a strong financial position to fund the advancement of multiple programs and Ted while expanding our discovery pipeline and operations into 2024 sub.
Subsequent to the end of the first quarter, we entered into a credit facility with Hercules were up to $75 million. Upon closing of this facility, we withdrew our $95 million an additional $20 million is available at the company's request through June 15, 2023 with an additional 25.
Million available upon the company's achievement of certain milestones.
The remaining $25 million available subject to lender approval. The company is under no obligation to draw funds in the future.
We believe this credit facility further increases our financial strength by reducing our dependence on capital markets, which provides us added street strategic and operational flexibility to advance our programs.
Turning to expenses, we reported research and development expenses of $17 $7 million for the quarter ended March 31st 2022, compared with $13 8 million for the same period last year the.
The increase in research and development expenses was primarily driven by personnel related costs license fees and clinical trial costs for D. R. D and there is there a one and B I D N zero-zero too.
These increases were offset by expenses related to manufacturing and IND, enabling studies for <unk> 001, and Vod and there. There are two that were incurred in the first quarter of 2021.
General and administrative expenses were $8 $4 million during the first quarter of 2022, compared with $6 $2 million for the same period last year the.
The increase in G&A expenses was driven by increases in personnel related costs, including severance share based compensation changes and consulting expenses.
Net loss was $25 $7 million for the first quarter of 2022, compared with $18 $5 million for the same period last year. The increase in net loss was driven by increased operating costs as well as lower revenue from our collaboration with dentists in the first quarter 2022.
Compared to 2021.
As of March 31st 2022, Meridian had approximately $42 9 million shares of common stock outstanding on an as converted basis.
Which included $27 2 million shares of common stock outstanding and approximately $15 7 million shares of common stock issuable. Upon the conversion of shares of series, a and series B.
With that I'll ask the operator to open the call for questions.
We will now begin the question and answer session.
You ask a question you May press Star then one on your telephone keypad.
You are using a speakerphone please pick up your handset.
To withdraw your question a question. Please press Star then two.
We will pause momentarily.
Assemble our roster.
Our first question comes from Chris Howerton with Jefferies. Please go ahead.
Excellent. Thanks, so much for taking the questions and congratulations on the clinical progress thus far.
We're my questions I think I'm pretty simple.
In terms of the the first question just wanted to clarify on the healthy volunteers data.
Hey, I'm colorblind, and I can't see everything all that well, but it looks like the.
The error bars are not consistent across throughout the line plot. So I'm just wondering if there's.
Is it a sparse dataset and that you know like there's only one patient at certain time points or I guess, just a little more color in terms of what constitutes the data.
Representing that graph.
And then the second question again, I think it's just a relatively simple clarification. When you think about the dosing between Oh, one and O. Two do you think of them as being equal potent you know it does a three Meg you know one equal three Meg and O. Two thank you.
Sure Thanks, Chris Hi.
So with respect to the IGF one question keep in mind. This is an interim analysis.
In.
The slide preceding the slides, you're referring to discuss that at this stage of the trial the top dose cohort. The <unk> cohort is ongoing and so we don't have data from later time points. There. So I think what youre seeing mostly reflects reflects that but we have completed three of the tenant.
Quint cohort.
And then.
The second question was Oh, two versus the old one and comparative potency. So these molecules have similar affinity for receptor, where we expect them to differ is in the pharmacokinetics, so we'd like to remind everyone.
One is it's very similar pharmacokinetics to temperature nomad and other.
First generation entrants in this class, but with the inclusion of half life extension, we believe VR DNO two hubs substantially longer half life as we've seen in our preclinical data.
So the question that the ongoing study will begin to answer is with that.
Similar dose, let's say, it's really kicked Dennis if we can get sustained exposure, we may not to be able to give us we may not have to get as big a dose over time. So the question.
Hello.
Dosing is really not just infinity receptor, but that very largely driven by the pharmacokinetics and that's why we're so excited about <unk> two.
We know that Vod and over one at southern animal or affinity and.
And in fact, we believe based on your oncology data that.
As you lower the dose much below three minutes per kg. It becomes PK limited improving affinity further is not likely to help.
What we think is going to help us improving the pharmacokinetics of that is what it does limit.
We're so excited about the idea of know too I'm looking forward to seeing the first in human data next quarter.
Okay very good I can't I mean, I guess I'll ask it. So you know your competitor Horizon is also announced that they are developing what they call a high concentration subcutaneous formulation as well you know how do you anticipate this changing your strategy.
G in the near term it though if at all excuse me yes.
So, let's let's review what that might mean right. So chip has is approved as well the loading doses 10 mix per gig and then seven and assuming doses of 20 banks for King.
And we know that the average patient size receiving deposits 75 milligrams. So that's a gram and a half of drug every three weeks.
Current marketed formulations 50 megs per mill.
So 150 milligrams at 50 make similar 30 millimeters three zero.
So that's that's a large volume right that that would be a large infusion to get the sub Q.
So what might one be able to achieve with a high concentration formulation now a typical target to shoot for would be about 150 mix per mill novel antibiotics can get there. Some cat in fact, both Oh I don't know two we've been able to formulate to 150 megs per mill without precipitation goodness capacity. So.
That's why I kind of standard threshold for high concentration.
There are two products, they've got higher than that 280 to 200 Megs per mill.
And left out of Actemra.
So that would be sort of an upside.
So, let's let's say, we can get we see temporary 150 mixed smell that takes the volume to 10 mills a need if it manages to meet the best ever obtained it makes per mile that could get down to seven and a half mills. So that's still a pretty substantial volume and it's not that's not something that the single.
Low volume injection for that we think the thresholds to know that we can point to.
<unk> products had been very successful shingles are lower as an injection.
So we're looking still.
At the approved doesn't it depends I.
Even assuming success of a high concentration formulation at an infusion or a large number of injections and so that's why we think that getting a lower dose and then take lower volume can enable us to deliver a compelling product profile with a low volume and less frequent subcutaneous product.
<unk>.
The next question is from Thomas.
SVP Leerink. Please go ahead.
Hey, guys. Good afternoon, thanks for taking the questions and congrats on the initial data here just maybe to start with one on the healthy volunteer data <unk> safety look.
Really clean.
Is there any additional color you can add on the hypertension or hyperglycemia that I know both deemed unrelated to study drug but just wondering if there's anything else you can add to that.
Yeah, so the hyperglycemia.
A patient who had hyperglycemia baseline.
And it was mild.
Continue to be mild and that's why it was deemed unrelated to study drug.
Yeah.
And then hypertension.
I mean these are kind of typical mild variations on often sees in a phase one study.
And again.
They were mild.
And really in.
Unrelated by study drug and not a concern to either the mass investigator or where to us.
Okay makes sense and then on the proof of concept.
Ted cohorts any additional color on patient enrollment here or are there any specific headwinds youre coming up against.
In terms of site activation, where patient enrollment and then I guess, maybe a follow up to that any early read on the types of 10 patients that youre investigators enrolling into the study and these patients that are more on the milder or or severe end of the active disease spectrum, where the investigators indicating the.
Greatest degree of interest at this point.
Sure Yep.
So in terms of enrollment.
You need two things right you need to get sites active and then you need to get patients enrolled at the site.
We.
We now have 11 sites open the majority of those had been in recent weeks. So we were expecting an uptick in site activation will earlier.
Now that we have these sites opened some of them have been opened for a few months, we've got a pretty nice track records to see what the enrollment rate looks like.
And it really is matching what we had expected a priori. So the hurdles we had in getting the sites activated which are for a variety of factors, we think we're well past.
Solve the issue and now the enrollment rate is performing just as we would hope so that's why we're very comfortable with our third our third quarter guidance.
With respect to the types of patients. We designed the study to ensure that we were not going to be enrolling patients that were less likely to show a benefit right. So we really mimic Z to power the phase III IV criteria.
And.
We're working with sites very experienced in this space.
And of course, keeping close oversight to make sure that no one outside the ie criteria are slipping out. So the study is really designed to ensure we're enrolling a similar patient population.
And.
Doesn't really happy with the engagement, we've seen from from sites the interest from patients and keep in mind.
<unk> is not often quickly available a lot of patients who either don't have access or it takes them a while so.
Whatever the reason, we're seeing really good interest and are pleased with the normal we've seen so far.
Okay got it and then just.
One last question on the.
The plans to add the three Meg per kg cohort four Ted patients like really interesting to think about the prospects of this in a subcutaneous formulation I guess, how much formulation work have you done to date around 001, and how difficult would it be to advance. This sub Q4, and how quickly could you potentially get this into the clinic.
Yeah. So.
We actually very quickly we shared this at some point last year were very quickly able to get a one or two for that matter to our target concentration of 150 Megs per mill and that's with goodness capacity.
Meaning that if it would be amenable to subcutaneous product. So we don't we don't see anything blocking us.
In terms of timing.
So when when could that advance forward really the key question is will the three Meg per kg dose work so.
So stay tuned for an update on our plans, but it's something that we're increasingly excited about and don't see any hurdles on the formulation front that would keep us from getting there.
Okay.
Okay got it I appreciate you guys, taking the questions and congrats again on the initial data.
Thanks, Tom.
And the next question is from Laura Chico with Wedbush. Please go ahead.
Hi, good afternoon. Thanks for taking the question I'm getting one from investors that I just wanted to clarify on with respect to owe to the timing is moving out to the third quarter and maybe that's just a narrowing but I guess I'm kind of curious if the the initial dosing is complete.
I guess are there remaining data items the process there on that what you read out just kind of clarifying the timing change on that and then with respect to all one I might've missed this I apologize if I did I don't see any of the pharmacokinetic data released when might we get a little bit more visibility on that aspect of the healthy volunteer data.
There was some question before about kind of half life differences it depends on different type of patient population. So I'm curious if you have any color there.
Sure. Thanks, Laura so for O too.
Narrowing the guidance, we had said mid year, meaning two Q3 Q.
We're clarifying that its third quarter, we did say dose escalation is completed so that means we got up to the top dose.
But keep in mind that with half life extension and indeed, the sample for a while to understand how well the half life extension technology is working.
So we just we just need to wait, but where we're very pleased with how the study is gone and then everything has gone quite well.
With respect to <unk> PK.
Again, we're still collecting data at the the top dose cohort.
But what we've seen so far are very consistent with the oncology data.
No actually it really excellent PK. So we see no signs of target mediate clearance, which is something that.
We got to watch out for but it looks great even at the low dose no evidence of anti drug antibodies again that that was true back in the oncology days for this molecule, but wonderful to see that again in our hands.
And then with respect to our.
Are there differences in across patient population so.
Just to remind everyone. We think about one versus top row and non these are both IGT want antibodies. So they're very similar they have indistinguishable pharmacokinetics in non human primates also.
College trials when both of these antibodies for oncology studies.
And but <unk> has never been in healthy volunteers and so.
When we look at the PK in thyroid eye disease patients instead of individual PK, which is how we prefer to think about pharmacokinetics and when I cited the oncology data in the nonhuman primate data that's individual PK. The Ted Pks is really a population PK based on sparse sampling. So it's really a different model.
And you can't really do an apples to apples comparison, what I can say is based on the preliminary data. We have seen we don't see any any obvious differences with between <unk> and.
<unk> and so we think we're going to have very similar PK when we get to 10 patients.
That's super helpful. John and maybe one last one if I can sneak it in there.
With the the proof of concept data coming in <unk> will we have full data at both the six week and the 12 week time point, thanks very much.
Sure, we're really focused on the six week time point, because again, where we were.
We're mimicking the topaz the dosing paradigm three week six so we dose on day, one we dose on day 21, and then we're measuring efficacy and day 42, a week six.
There is a near term follow up at week 12, but we're not dosing between week six and week 12, and so in terms of doing the kinds of cross trial comparisons that we all are interested in really have to look at the six week time point and not the 12 week lots of interesting information will come out of the 12 week follow up but we're not guiding to include that in the top line.
Not really as soon as we have the six week data on both the tenant and for taking 20 Meg per kg cohorts, we'll have a rich data set that we'll be excited to share.
Thanks very much.
Our next question is from Rami.
Lifestyle capital. Please go ahead.
Hey, guys. Thanks for taking my questions and congrats on the early data.
Going off the previous question.
The three Meg kicked up Youre. Your one has shown to be efficacious and sub acute therapy I guess does that affect your development plan with your two at all or is it too early to tell.
Yeah, well, what we like about our approach here is we have lots of options lots of shots on goal.
If we can get a one to a sub Q.
That three Meg per kg cohort works and no one can move forward in the sub Q product presentation, and a sub Q injection right. We're trying to get to a low volume injection as opposed to a larger volume infusion. The nice thing about that is that there's potential that can move very quickly.
And it could be the first sub Q entered and thyroid eye disease with O. Two with half life extension, there is an opportunity to reduce the frequency and come up with the most convenient possible product presentation.
And so we would be interested in moving that forward as well.
But we should add.
Is that right. So it's the only the only IGF oner antibody with athletic extension of market. So it could be really heartbeat.
Definitely makes sense.
I guess another question. If you don't mind can you remind us the plasma levels of the IGF, one biomarker generally correlate with clinical accuracy and Ted.
Well, it's because tempo was never dose range, we can't point to a dose response relationship.
So really what we can do is look back at all the IGF one our antibodies in the past so I'm very consistently and based on the underlying biology, when you inhibits IGF, one or when you buy it when you bind and blocks the receptor a plasma levels of IGF. One go up so it's a marker for target engagement doesn't tell us anything specifically about the <unk>.
Dizzy allergy. So we can't we can't draw that either mechanistic or quantitative link, but the fact that we're seeing a maximal response with a same a high rate of onset of the increase in all of these doses and given the fact that we have southern animal or affinity and we're well above 10 micrograms per mil.
Exposure, if you look back at the old oncology data for this drug.
It's very reasonable to hypothesize that were saturating the receptor and could deliver full efficacy at this dose that I think that that's really what drove our excitement for announcing that we'll be starting a three meg per kg cohort.
With that in the fourth quarter.
It makes a lot of time right.
Again, if you have a question. Please press star then.
One.
Next question is from Jason Butler with JMP Securities. Please go ahead.
Hi, Thanks for taking the questions.
Maybe one that you still need to see more data from but any thoughts that based on the data you have today and what were their dosing frequency with the three Meg per kg Q formulation would be would it be the same Q3 weeks or it could it be different to that and then I'm.
Just at this point it is at least one of the scenarios for for our one that you conduct a registration study or studies that incorporated.
The sub Q and the IV formulations you'd go to FDA in parallel with both formulations.
Yes.
I think it's a little too early to answer both questions Declaratively right, we need to see some more data.
But theres.
Theres, a tradeoff right, but when you think about a sub Q product you can there's a tradeoff between volume and frequency. So you can have a lower volume more frequently or a larger volume less frequently and when we see data from the <unk> cohort. We will have some interesting interesting decisions to make as to what we will study.
Going forward.
Now of course, when we think about how can we get this approved right that the goal as I said would be to get this to market as fast as possible and that will very much feed into our thinking as to what kind of dosing frequency will do and what level of evidence is required to get the sub Q.
Product approved so stay tuned, but we're really excited that there's potential that this could move forward quickly.
Great. Thanks for taking my question and congrats on the progress in the data.
Thanks, Jason.
This concludes our question and answer session I would like to turn the conference back over to Jonathan violin for any closing.
Remarks.
Thank you and thanks, everyone for joining us today as I hope you've heard we're very excited about both the ongoing progress that we're making across our Ted programs and the multiple upcoming data readouts. So we'll look forward to updating you as our programs events and with that we'll close the call.
The conference has now concluded. Thank you for attending today's presentation you may now disconnect.
Yeah.